Low levels of high-density lipoprotein cholesterol(HDL-C) are associated with the development of cardiovascular disease (CVD). In addition, under the state of obesity, HDL particles can be modified to generate dysfunctional HDL-C which is a more important risk factor for CVD. Despite strong evidence of the protective effect of HDL-C to CVD, there are no potent HDL elevators available. However, new insights in HDL biology have recently allowed the development of promising actions aimed to enhance HDL function and promote atherogenesis regression in obesity. Growing burdens of HDL-C action and new generation agents which are thought to be able to raise HDL-C or enhance its function are discussed in this review.

Keywords: Obesity, High-density lipoprotein cholesterol,
Action mechanism, New generation agent

1. Kontogianni MD, Panagiotakos DB, Skopouli FN. Dose body mass index reflect adequately the body fat content in perimenopausal women? Maturitas 2005;51:307-13.
   
2. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
3. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
   
4. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98.
   
5. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2009;30:151-5.
   
6. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376-83.
   
7. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211 -28.
   
8. Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 2001;42:1717-26.
   
9. Dobi?sov? M, Frohlich J. Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Physiol Res 1998;47:387-97.
   
10. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 2009;50:S201-6.
    
11. Glueck CJ, Taylor HL, Jacobs D, Morrison JA, Beaglehole R, Williams OD. Plasma high-density lipoprotein cholesterol: association with measurements of body mass. The Lipid Research Clinics Program Prevalence Study. Circulation 1980;62:62-9.
12. Despr?s JP, Moorjani S, Ferland M, Tremblay A, Lupien PJ, Nadeau A, et al. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis 1989;9:203-10.
    
13. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003;52:172-9.
    
14. Smith JD. Myeloperoxidase, inflammation, dysfunctional high-density lipoprotein. J Clin Lipidol 2010;4:382-8.
    
15. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti -inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
    
16. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110-22.
    
17. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, atherosclerosis. N Engl J Med 2011;364:127-35.
    
18. Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002;16:24-8.
    
19. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring) 2007;15:2875-88.
    
20. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring) 2008;16:1152-60.
    
21. Wang H, Peng D. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids in Health Dis 2011;10:176-85.
    
22. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94:206-18.
    
23. Zhang Y, McGillicuddy FC, Hinkle CC, O’Neill S, Glick JM, Rothblat GH, et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010;121:1347-55.
    
24. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-5.
    
25. Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NC, Mooradian AD. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochim Biophys Acta 2003;1623:120-8.
    
26. Beers A, Haas MJ, Wong NC, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. Biochemistry 2006;45:2408-13.
    
27. Wellington CL, Brunham LR, Zhou S, Singaraja RR, Visscher H, Gelfer A, et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res 2003;44:1470-80.
    
28. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005;115:1333-42.
    
29. Tsujita M, Wu CA, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J Lipid Res 2005;46:154-62.
    
30. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-31.
    
31. Franceschini G, Sirtori CR, Capurso A 2nd, Weisgraber KH, Mahley RW. A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66: 892-900.
    
32. Nicholls SJ, Uno K, Kataoka Y, Nissen SE. ETC-216 for coronary artery disease. Expert Opin Biol Ther 2011;11:387-94.
    
33. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47:992-7.
    
34. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300.
    
35. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16.
    
36. Psaty BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA 2008;299:1474-6.
    
37. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009;150:2211-9.
    
38. Roche. Roche provides update on Phase III study of dalcetrapib. [accessed 2012 September 28]. Available from: URL: http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm
39. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.
    
40. Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, Shah S, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther 2012;91:109-22.
    
41. The MRC/Cancer Research UK/BHF Clinical Trial Service Unit & Epidemiological Studies Unit. Welcome to the THRIVE Study. [accessed 2012 September 28]. Available from: URL: http://www.thrivestudy.org/index.htm
42. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther 2012;26:71-5.